How can we bring high drug doses to the lung?

Eur J Pharm Biopharm. 2014 Jan;86(1):1-6. doi: 10.1016/j.ejpb.2013.11.005. Epub 2013 Dec 1.

Abstract

In the last decades, dry powder inhalation has become a very attractive option for pulmonary drug delivery to treat lung diseases like cystic fibroses and lung infections. In contrast to the traditional pulmonary application of drugs for asthma and chronic obstructive pulmonary disease, these therapies require higher lung doses to be administered. The developments and improvements toward high dose powder pulmonary drug delivery are summarized and discussed in this chapter. These include the invention and improvement of novel inhaler devices as well as the further development of formulation principles and new powder engineering methods. The implementation of these strategies is subsequently described for some prototypes and formulations in research and development stage as well as for already marketed dry powder products. Finally, possible adverse effects that can occur after inhalation of high powder doses are shortly addressed.

Keywords: Antibiotic inhalation; Dry powder inhalation; High dose delivery; Inhalation devices; Lung delivery; Particle engineering; Pulmonary drug delivery.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Inhalation
  • Cystic Fibrosis / drug therapy
  • Cystic Fibrosis / metabolism
  • Dose-Response Relationship, Drug
  • Drug Delivery Systems / adverse effects
  • Drug Delivery Systems / instrumentation
  • Drug Delivery Systems / methods*
  • Dry Powder Inhalers
  • Humans
  • Lung / drug effects
  • Lung / metabolism*
  • Metered Dose Inhalers
  • Pharmaceutical Preparations / administration & dosage*
  • Pharmaceutical Preparations / chemistry
  • Respiratory Tract Infections / drug therapy
  • Respiratory Tract Infections / metabolism

Substances

  • Pharmaceutical Preparations